Frontlight ResearchEarly access
TerminatedNo phase
Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
Key facts
- Who runs it
- OHSU Knight Cancer Institute
- Where
- Portland, United StatesSee the site
- Trial code
- Status
- Terminated
- People taking part
- 9 people enrolled
- Started
- 7 Feb 2019
- Ended
- 11 Jan 2024
- Type of study
- Interventional
- Treatments tested
- Quality-of-Life Assessment
- Questionnaire Administration
- Stereotactic Body Radiation Therapy
- Record updated
- 7 March 2025
- Why it stopped
- PI decision
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Ability to understand and the willingness to sign a written informed consent document
- Must be listed or recommended to be listed for orthotopic liver transplantation at the participating institution
- Have a Child-Pugh (CP) score >= B8
- Eastern Clinical Oncology Group (ECOG) performance status =< 2, or Karnofsky performance scale > 60
- Must have a life expectancy > 12 weeks
- Safe radiation treatment planning parameters that adhere to all organs at risk constraints per section 5.1 of the protocol. If normal organs at risk constraints (including at least 700cc of uninvolved liver) are unable to be met at the lowest dose modification (30 Gy in 5 fractions), the patient is deemed ineligible for SBRT and deemed a screen failure
- Except for prior radiotherapy or radioembolization, other prior therapies to previously treated lesions, are permitted
- People of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of SBRT. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
- Participants of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year without an alternative medical cause; Note: Abstinence is acceptable if this is the preferred contraception for the participant
- No other prior invasive malignancy is allowed except for the following: adequately treated basal (or squamous cell) skin cancer, in situ breast or cervical cancer. Stage I or II invasive cancer treated with a curative intent without evidence of disease recurrence for at least five years
Who cannot take part
- Prior radiotherapy to the upper abdomen or radioembolization of the liver, or prior thermal ablation to the target lesion
- Participation in another concurrent treatment protocol
- For fiducial marker placement:; Have a gold allergy; Any coagulopathy preventing safe fiducial placement
- Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring adverse events (AEs) or compromise the ability of the patient to give written informed consent
- Participants have any one of the following liver tumor characteristics:; Have > 5 liver tumors, or; Maximal diameter > 5 cm
- Complete obstruction of portal venous flow to the segment of liver that includes the target lesion
- Contraindication to both contrast enhanced magnetic resonance imaging (MRI) and contrast enhanced computed tomography (CT) (i.e. unable to undergo follow-up imaging or SBRT treatment planning)
- Participant is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment
Where in United States
- OHSU Knight Cancer InstitutePortland, United States
About the trial
What the trial wants to find out
This trial studies how well stereotactic body radiation therapy works in treating patients with liver cancer. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue.
The group in the trial
- Treatment (SBRT)Treatment being tested
Patients undergo SBRT on days 1, 3, 5, 7, and 9 in the absence of disease progression or unacceptable toxicity.
Treatment: Quality-of-Life Assessment, Questionnaire Administration, and Stereotactic Body Radiation Therapy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Pilot Study to Assess Feasibility of Hypofractionation and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients Awaiting Liver Transplantation
- Record updated
- 7 March 2025